Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study

Table 1 Baseline characteristics

	FDC (n = 80)	MTR (n = 163)
Gender (female)	32.5% (26)	33.7% (55)	0.037 P = 0.8471
Italian origin	73.8% (59)	75.5% (123)	0.083 P = 0.7731
Comorbidities
HCV	12.5% (10)	8.6% (14)	0.918 P = 0.3381
HBV	2.5% (2)	1.2% (2)	0.535 P = 0.4651
Osteoporosis	1	0
Injecting drugs addiction	0	2
Diabetes	1	2
Kidney failure	1	0
Psychiatric disorders	6.2% (5)	4.9% (8)	0.190 P = 0.6631
Others diseases	18.7% (15)	27.0% (44)	1.976 P = 0.1601
Proportions of treated with
Atripla	37.5% (30)	28.2% (46)	2.141 P = 0.1431
Combivir	7.5% (6)	21.5% (35)	7.439 P = 0.0061
Kivexa	30.0% (24)	19.6% (32)	3.239 P = 0.0721
Truvada	25.0% (20)	30.7% (50)	0.839 P = 0.3601
Undetectable HIV-RNA at baseline	75.0% (60)	76.7% (125)	0.084 P = 0.7721
CD4 count at baseline	698.5 (SD 295.27)	671.6 (SD 268.87)	P = 0.4922
Mean age (yr)	47.3 (SD 10.77)	47.06 (SD 9.47)	P = 0.8392
Years of HAART	8.7 (SD 4.26)	8.7 (SD 4.85)	P = 0.9532
HAART pills number	2.4 (SD 1.35)	2.9 (SD 1.56)	P = 0.0162
Non HAART pills number	1.4 (SD 2.71)	1.1 (SD 1.95)	P = 0.4092
Total pills number	3.8 (SD 2.935)	4.0 (SD 2.63)	P = 0.5722

Proportions (n) or means (SD) as appropriate.

¹N-1 chi-square;

²T test for independent samples. HIV: Human immunodeficiency virus; HAART: Highly active antiretroviral therapy; HBV: Hepatitis B virus; HCV: Hepatitis C virus.